Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10617584 | 0.92 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL1775891 | 0.85 | — | — | |
| SCHEMBL11719502 | 0.78 | CYP3A4 (0.36) | ALDH1A1TSHRTDP1 | |
| SCHEMBL11759125 | 0.74 | LMNA (0.39) | ALDH1A1TSHR | |
| SCHEMBL671120 | 0.71 | — | — | |
| SCHEMBL11458518 | 0.71 | — | — | |
| SCHEMBL1627599 | 0.71 | TP53 (0.42) | TSHRTDP1 | |
| SCHEMBL11063566 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL11017156 | 0.71 | — | — | |
| SCHEMBL11639851 | 0.71 | CA12 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923563-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-12 | — | — | US | disclosed |
| EP-1808432-B1 | AMORPHOUS FORM OF CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-20090203916-A1 | Amorphous object of cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1808432-A1 | AMORPHOUS OBJECT OF CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203916-A1 | Amorphous object of cinnamide compound | BACE1, APP, PSEN1 | ALDH1A1 442/4885TSHR 4763/4885TDP1 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.